Clofazimine
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Using the report structure from your v5 prompt, I’ll flag upfront: original_indications and taiwan_regulatory.licenses are both empty in this Evidence Pack, so “Leprosy” below is stated as general pharmacological background knowledge (also corroborated by the literature entries in this same pack — e.g. PMID 12616942 references leprosy MDT with clofazimine), not extracted from a Taiwan license record. I did not guess at anything not otherwise supportable.
Clofazimine: From Leprosy to Pneumocystosis
One-Sentence Summary
Clofazimine is a riminophenazine antimycobacterial historically used to treat leprosy (Hansen’s disease) as part of WHO multidrug therapy. The TxGNN model predicts potential efficacy against Pneumocystosis, but this is currently supported by only 1 clinical trial (which actually targets a different pathogen — MAC, not Pneumocystis) and 4 publications, none of which provide direct evidence of clofazimine treating or preventing Pneumocystis infection. Evidence quality is low, and the prediction rationale itself suggests the score may reflect a knowledge-graph confounding artifact rather than a genuine mechanistic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Leprosy (Hansen’s disease) — general pharmacological knowledge; no Taiwan-specific license text available |
| Predicted New Indication | Pneumocystosis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| Taiwan Market Status | Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on known information, Clofazimine is a riminophenazine-class antimycobacterial agent used primarily in the WHO multidrug therapy (MDT) regimen for leprosy (Mycobacterium leprae infection), and its efficacy in that indication has been well established for decades. Mechanistically, it binds mycobacterial DNA, generates reactive oxygen species, and stabilizes cell membranes — actions oriented specifically toward mycobacterial pathogens.
Pneumocystis jirovecii, the causative organism of pneumocystosis, is a fungus-like organism that is biologically and pharmacologically distinct from Mycobacterium leprae. There is no established pharmacological pathway connecting clofazimine’s antimycobacterial mechanism to antifungal or anti-Pneumocystis activity.
Per the repurposing rationale accompanying this prediction, the model’s high confidence score likely arises from co-occurrence bias in the underlying knowledge graph: in HIV/AIDS literature, prophylaxis against Mycobacterium avium complex (MAC) and prophylaxis/treatment of Pneumocystis carinii pneumonia (PCP) are frequently discussed together, since both are common opportunistic infections in the same immunocompromised patient population. Clofazimine’s well-documented role as a MAC prophylactic agent may have caused the model to associate it with PCP by proximity in the literature, rather than through any direct biological mechanism. This substantially weakens the biological plausibility of the prediction and is the main driver of the Hold recommendation below.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002058 | N/A | Completed | N/A | Randomized prophylaxis trial of clofazimine to prevent Mycobacterium avium complex (MAC) infection in HIV-positive patients. Targets MAC, not Pneumocystis; relevance graded C (low) — included in this evidence set only because both are AIDS-related opportunistic infection topics. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11363899 | 1996 | Review | PI Perspective | General review of opportunistic infection updates in AIDS; no clofazimine–Pneumocystis specific data available. |
| 8501340 | 1993 | Cohort/clinical study (MAC, not PCP) | The Journal of Infectious Diseases | Community-based trial of clofazimine prophylaxis for disseminated MAC infection in HIV patients with a prior PCP episode or CD4 ≤100/mm³; evaluates MAC prevention, not Pneumocystis treatment. |
| 6299154 | 1983 | Case report | Annals of Internal Medicine | Hemophilia patient with PCP and disseminated MAC bacteremia; clofazimine’s role, if any, is not tied to PCP management. |
| 2714863 | 1989 | Case report | Infection | AIDS patient with M. kansasii lung disease complicated by PCP, treated with a multidrug regimen (including clofazimine) plus TMP-SMX for PCP; clofazimine’s independent contribution to PCP resolution is not established. |
Safety Considerations
Drug Interactions: 111 total interactions identified for Clofazimine. Notable examples:
- Major: Cisapride, Dolasetron (additive QT-prolongation/arrhythmia risk — clofazimine itself is associated with QT prolongation)
- Moderate: Famotidine, Loperamide, Bisacodyl, Clarithromycin, Levofloxacin, Picosulfuric acid, and several osmotic/laxative agents (polyethylene glycol with electrolytes, castor oil, glycerin, lactitol, lactulose, magnesium citrate, magnesium hydroxide, mineral oil), plus 5-HT3 antiemetics (Granisetron, Ondansetron, Palonosetron)
- Minor: Metronidazole
Detailed prescribing warnings and contraindications (DG001, Blocking severity) are not currently available in this evidence pack — please refer to the official package insert for complete safety information before any clinical use.
Other Predicted Indications Screened (Lower Priority)
For completeness, two additional TxGNN candidates were screened in this evidence pack but are not the focus of this report, given weaker evidence:
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 2 | Malaria | 99.60% | L4 | Research Question | Only in vitro activity reported for clofazimine analogues (not clofazimine itself); no clinical trials; most retrieved literature is about drug-resistant tuberculosis and is not actually malaria-relevant. |
| 3 | Gastrin secretion abnormality | 99.57% | L5 | Hold | No clinical trials or literature support whatsoever — score is a pure model output with no biological rationale. |
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence quality for the pneumocystosis prediction is low (L4): the sole clinical trial targets MAC prophylaxis rather than Pneumocystis, and none of the four literature citations demonstrate clofazimine efficacy against Pneumocystis jirovecii. The prediction rationale itself indicates the high TxGNN score likely reflects knowledge-graph co-occurrence bias (MAC and PCP prophylaxis frequently discussed together in AIDS literature) rather than a genuine mechanistic link.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (DG001, Blocking) — required before any S1 safety evaluation can begin
- Confirmed mechanism-of-action data for Clofazimine (DG002, High)
- Direct preclinical or in vitro evidence of clofazimine activity against Pneumocystis jirovecii specifically (not MAC)
- If pursuing further research, a dedicated study design that isolates Pneumocystis outcomes from MAC co-infection confounding
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.